

Claims

b 1 1. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising a non-steroidal suppressor
b 7 of angiogenesis in an amount effective to ^{reduce} ~~inhibit~~ hair
8 growth.

1 2. The method of claim 1, wherein said suppressor
2 is a compound that interferes with the action of heparin
3 sulfate proteoglycans.

1 3. The method of claim 2, wherein said compound is
2 an inhibitor of sulfotransferase.

1 4. The method of claim 2, wherein said compound is
2 a heparin binding antagonist.

1 5. The method of claim 2, wherein said compound is
2 a copper chelator.

1 6. The method of claim 1, wherein said suppressor
2 is a compound that interferes with the action of histamine.

1 7. The method of claim 6, wherein said compound is
2 an inhibitor of histidine decarboxylase.

E. J. 1 8. The method of claim 6, wherein said compound is
2 an inhibitor of mast cell degranulation.


1 9. The method of claim 6, wherein said compound is
2 a histamine receptor antagonist.

1 10. The method of claim 1, wherein said suppressor
2 is a compound that interferes with the action of angiotensin
3 II.

1 11. The method of claim 10, wherein said compound
2 is an inhibitor of angiotensin converting enzyme.

1 12. The method of claim 10, wherein said compound
2 is an angiotensin II receptor antagonist.

1 13. The method of claim 1, wherein said suppressor
2 is a compound that interferes with the action of
3 prostaglandin E1.

 1 14. The method of claim 1, wherein said compound is
2 an inhibitor of prostaglandin synthetase.

1 15. The method of claim 1 wherein said suppressor
2 interferes with the action of Substance P.

1 16. The method of claim 15, wherein said compound
2 is an NK1 receptor antagonist.

1 17. The method of claim 1, wherein said suppressor
2 interferes with the action of platelet activating factor.

1 18. The method of claim 17, wherein said compound
2 is a platelet activating factor receptor antagonist.

1 19. The method of claim 1, wherein said suppressor
2 interferes with the action of 12-HETrE.

1 20. The method of claim 19, wherein said compound
2 is an inhibitor of cytochrome P450 reductase.

1 21. The method of claim 1, wherein said composition
2 further comprises vehicle.

1 22. The method of claim 1, wherein the
2 concentration of said suppressor in said composition is
3 between 1% and 30% by weight.

1 23. The method of claim 1, wherein the composition
2 provides a reduction in hair growth of at least 20% when
3 tested in the Golden Syrian hamster assay.

1 24. The method of claim 1, wherein the composition
2 provides a reduction in hair growth of at least 50% when
3 tested in the Golden Syrian hamster assay.

1 25. The method of claim 1, wherein the composition
2 provides a reduction in hair growth of at least 70% when
3 tested in the Golden Syrian hamster assay.

1 26. The method of claim 1, wherein the suppressor
2 is applied to the skin in an amount of from 100 to 3000
3 micrograms of said inhibitor per square centimeter of skin.

1 27. The method of claim 1, wherein said mammal is a
2 human.

27
1 ~~28.~~ The method of claim 27, wherein said area of
2 skin is on the face of the human.

28
1 ~~29.~~ The method of claim 28, wherein said human is a
2 woman suffering from hirsutism.

b 1 ~~30.~~ A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an inhibitor of
7 sulfotransferase in an amount effective to ^{reduce} ~~inhibit~~ hair
8 growth.

30
1 ~~31.~~ The method of claim 30, wherein said inhibitor
2 is p-nitrocatechol.

31
1 ~~32.~~ The method of claim 30, wherein said inhibitor
2 is catechin.

b 1 ~~33.~~ A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising a heparin binding
7 antagonist in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

33
1 ~~34.~~ The method of claim 33, wherein said antagonist
2 is pentosan polysulfate.

1 ³⁴
2 ~~35.~~ The method of claim ³² 33, wherein said antagonist
is quinacrine.

b 1 ^{reducing}
2 36. A method of ~~inhibiting~~ mammalian hair growth
which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising a copper chelator in an
7 amount effective to ^{reduce} ~~inhibit~~ hair growth.

1 ³⁶
2 ~~37.~~ The method of claim ³⁵ 36, wherein said copper
chelator is bathocuproine disulfonate.

1 ³⁷
2 ~~38.~~ The method of claim ³⁵ 36, wherein said copper
chelator is diethylenetriamine pentaacetic acid.

b 1 ^{reducing}
2 39. A method of ~~inhibiting~~ mammalian hair growth
which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an inhibitor of histidine
7 decarboxylase in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

1 ³⁹
2 ~~40.~~ The method of claim ³⁸ 39, wherein said inhibitor
is O-p-nitrohydroxylamine.

1 ⁴⁰
2 ~~41.~~ The method of claim ³⁸ 39, wherein said inhibitor
is α -fluoromethylhistidine.

b
1 42. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an inhibitor of mast cell
7 degranulation in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

Sub 42
1 ~~42~~ 43. The method of claim 42, wherein said inhibitor
2 is mycophenolic acid.

1 ~~43~~ 44. The method of claim 42, wherein said inhibitor
2 is bromocryptine.

1 ~~44~~ 45. The method of claim 42, wherein said inhibitor
2 is cromoglycate.

b
1 ¹/~~45~~ 46. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising a histamine receptor
7 antagonist in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

Sub 46
1 ~~46~~ 47. The method of claim 46, wherein said antagonist
2 is terfenadine.

1 ~~47~~ 48. The method of claim 46, wherein said antagonist
2 is tripeleennamine.

1 ⁴⁸~~49~~. The method of claim ⁴⁵~~46~~, wherein said antagonist
2 is chlorpheniramine.

1 ⁴⁹~~50~~. The method of claim ⁴⁵~~46~~, wherein said antagonist
2 is cimetidine.

b 1 ⁵¹~~51~~. A method of ^{reducing}~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an inhibitor of
7 angiotensin converting enzyme in an amount effective to
8 ^{reduce}~~inhibit~~ hair growth.

1 ⁵¹~~52~~. The method of claim ⁵⁰~~51~~, wherein said inhibitor
2 is enalapril.

1 ⁵²~~53~~. The method of claim ⁵⁰~~51~~, wherein said inhibitor
2 is lisinopril.

b 1 ⁵⁴~~54~~. A method of ^{reducing}~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an angiotensin II receptor
7 antagonist in an amount effective to ^{reduce}~~inhibit~~ hair growth.

1 ⁵⁴~~55~~. The method of claim ⁵³~~54~~, wherein said antagonist
2 is a 1,4- substituted indole.

- 1 ⁵⁵~~56~~. The method of claim ⁵³~~54~~, wherein said antagonist
2 is a dihydropyridine derivative.
- 1 ⁵⁶~~57~~. The method of claim ⁵⁵~~56~~, wherein said antagonist
2 is nifedipine.
- 1 ⁵⁷~~58~~. The method of claim ⁵³~~54~~, wherein said antagonist
2 is a triazolinone derivative.
- 1 ⁵⁸~~59~~. The method of claim ⁵⁷~~58~~, wherein said
2 triazolinane derivative has a side chain at the N⁴ position.
- 3 ⁵⁹~~60~~. The method of claim ⁵³~~54~~, wherein said antagonist
4 is a tetrahydroisoquinoline carboxylic acid.
- 5 ⁶⁰~~61~~. The method of claim ⁵³~~54~~, wherein said antagonist
6 is an imidazopyridine derivative.
- 7 ⁶¹~~62~~. The method of claim ⁶⁰~~61~~, wherein said
8 imidazopyridine derivative is a tetrahydroimidazopyridine
9 carboxylic acid analog.
- 10 ⁶²~~63~~. The method of claim ⁵³~~54~~, wherein said antagonist
11 is Losantan.

b 1 64. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising an inhibitor of
7 prostaglandin synthetase in an amount effective to ^{reduce} ~~inhibit~~
8 hair growth.

63
64. The method of claim 64, wherein said inhibitor is piracetam.

c 1 65. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 ^{topically} applying to said area of skin a dermatologically
6 acceptable composition comprising an NK¹ receptor antagonist
7 in an amount effective to ^{reducing} ~~inhibit~~ hair growth.

I 64
66. The method of claim 65, wherein said antagonist is (3aR,7aR)-7,7,-diphenyl-2-[1-imino-2-(2-methoxyphenyl)ethyl]perhydroisoindol-4-one.

c 67
68. The method of claim 66, wherein said antagonist is cis-2-(diphenylmethyl)-N-[(2-methoxy-phenyl)]-methyl]-1-azabicyclo[2,2,2]octan-3-amine.

69. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising a platelet activating factor receptor antagonist in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

70. The method of claim 69, wherein said antagonist is tioconazole.

71. The method of claim 69, wherein said antagonist is (3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[2-f]-[1,2,4]triazolo-[4,3-a][1,4]-diazepin-2-yl-1-(4-morpholinyl)-1-propanone.

72. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising an inhibitor of cytochrome P450 reductase in an amount effective to ^{reduce} ~~inhibit~~ hair growth.

73. The method of claim 72, wherein said inhibitor is clotrimazole.

b

1 74. A method of ^{reducing} ~~inhibiting~~ mammalian hair growth
2 which comprises
3 selecting an area of skin from which reduced hair
4 growth is desired; and
5 applying to said area of skin a dermatologically
6 acceptable composition comprising, in an amount effective to
7 reduce hair growth, a compound selected from the group
8 consisting of phenyl-ethylene derivatives such as tamoxifen
9 and nafoxidine; irsogladine; the synthetic laminin peptide,
10 CDPGYIGSR-NH₂; radicicol; eponemycin; fumagillin (O-
11 (chloroacetyl-carbamoyl)fumagillol) and synthetic analogues
12 thereof; recombinant human platelet factor-4 and related
13 peptides; protamine; sulfated chitin derivatives;
14 diaminoanthraquinone derivatives; thrombospondin; quinoline-
15 3-carboxamide (linomide); analogues of diatamycin A; and
16 aurintricarboxylic acid.

5/12/86

ADD 6/5

add H4

add F4